Actively Recruiting
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
Led by Wang Yusheng · Updated on 2025-04-04
146
Participants Needed
3
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)
CONDITIONS
Official Title
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Preterm infants with birth weight less than or equal to 2000 grams or gestational age less than or equal to 32 weeks
- Bilateral type 1 Retinopathy of Prematurity with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3+ disease; Zone II, stage 2+, 3+ disease; or Aggressive ROP (A-ROP)
You will not qualify if you...
- Preterm infants with stage 4 or 5 Retinopathy of Prematurity in one or both eyes
- Prior surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, or vitrectomy
- Previous exposure to any intravitreal or systemic anti-VEGF agent by the patient or mother during pregnancy
- Use of other investigational drugs (except vitamins and minerals) within 30 days or 5 half-lives of the drug
- Active eye infection within 5 days before or on the day of first treatment
- History of hypersensitivity to investigational treatments or similar drugs
- Contraindication for intravitreal injection
- Ocular structural abnormalities affecting efficacy assessments
- Other congenital or systemic conditions posing significant risk to visual function
- Medical conditions or circumstances affecting study participation or efficacy assessments as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University
Xi'an, Shaanxi, China, 710032
Actively Recruiting
2
Department of Ophthalmology, Xijing Hospital, Air Force Military Medical University
Xi'an, Shaanxi, China, 710032
Actively Recruiting
3
Department of Ophthalmology, Xianyang Rainbow Hospital
Xianyang, Shaanxi, China, 712000
Actively Recruiting
Research Team
W
Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here